Multiple Sclerosis Therapeutics Market Analysis By Drug Class (Immunomodulators, Immunosuppressant, Copaxone, Avonex, Gilenya, Tysabri, Betaseron, Tecfidera, Rebif, Ampyra, Aubagio, Extavia, Plegridy, Alemtuzumab, Glatopa, Siponimod, Ocrelizumab, Laquinimod, Zinbryta), By Mode of Administration (Oral, Injectable, Intravenous) And Segment Forecasts To 2024

Table of Content

Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Scope & Assumptions
1.3 List of Data Sources
Chapter 2 Executive Summary
Chapter 3 Multiple sclerosis therapeutics Industry Outlook
3.1 Market Segmentation
3.2 Market Size and Growth Prospects
3.2.1 Market driver analysis
3.2.1.1 Increasing global prevalence of target disease
3.2.1.2 Awareness programs
3.2.1.3 Presence of reimbursement policies.
3.2.1.4 Strong product pipeline.
3.2.2 Market restraint analysis
3.2.3 Multiple sclerosis therapeutics market - Key market restraint analysis
3.2.3.1 Side-effects and risks
3.2.3.2 High price
3.3 Key Opportunities Prioritized
3.4 Multiple sclerosis therapeutics - PESTEL Analysis
Chapter 4 Multiple sclerosis therapeutics Drug Class Outlook
4.1 Multiple sclerosis therapeutics Market Share by Drug Class, 2015 & 2024
4.2 Immunomodulators
4.2.1 Immunomodulators market, 2012 - 2024 (USD Million)
4.3 Immunosuppressant
4.3.1 Immunosuppressantmarket, 2012 - 2024 (USD Million)
第五章多发性硬化的治疗模式Administration Outlook
5.1 Multiple sclerosis therapeutics Market Share by Mode of Administration, 2015 & 2024
5.2 Oral
5.2.1 Oral market, 2012 - 2024 (USD Million)
5.3 Injectable
5.3.1 Injectablemarket, 2012 - 2024 (USD Million)
5.4 Intravenous
5.4.1 Intravenousmarket, 2012 - 2024 (USD Million)
Chapter 6 Multiple sclerosis therapeutics Regional Outlook
6.1 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
6.2 North America
6.2.1 North America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.2.2 U.S.
6.2.2.1美国多发性硬化症治疗标记t, 2012 - 2024 (USD Million)
6.2.3 Canada
6.2.3.1 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
6.3 Europe
6.3.1 Europe Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.3.2 UK
6.3.2.1 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.3.3 Germany
6.3.3.1 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4 Asia Pacific Multiple sclerosis therapeutics Market
6.4.1 Asia Pacific Multiple sclerosis therapeutics Market, 2012 - 2020 (USD Million)
6.4.2 China
6.4.2.1 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.4.3 India
6.4.3.1 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.5 Latin America
6.5.1 Latin America Multiple sclerosis therapeutics Market, 2012 - 2022 (USD Million)
6.5.2 Brazil
6.5.2.1 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6 MEA
6.6.1 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
6.6.2 South Africa
6.6.2.1 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
Chapter 7 Competitive Landscape
7.1 Teva
7.1.1 Company Overview
7.1.2 Financial Performance
7.1.3 Product Benchmarking
7.1.4 Strategic Initiatives
7.2 Pfizer
7.2.1 Company Overview
7.2.2 Financial Performance
7.2.3 Product Benchmarking
7.2.4 Strategic Initiatives
7.3 Biogen Idec
7.3.1 Company Overview
7.3.2 Financial Performance
7.3.3 Product Benchmarking
7.3.4 Strategic Initiatives
7.4 Bayer Healthcare
7.4.1 Company Overview
7.4.2 Financial Performance
7.4.3 Product Benchmarking
7.4.4 Strategic Initiatives
7.5 Genzyme (SANOFI)
7.5.1 Company Overview
7.5.2 Financial Performance
7.5.3 Product Benchmarking
7.5.4 Strategic Initiatives

List of Tables

TABLE 1 Multiple sclerosis therapeutics market - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Multiple sclerosis therapeutics market, by treatment, 2012 - 2024 (USD Million)
TABLE 3 Multiple sclerosis therapeutics market, by region, 2012 - 2024 (USD Million)
TABLE 4 Multiple sclerosis therapeutics market - Key market driver analysis
TABLE 5 Immunomodulators market: Drug overview
TABLE 6 Immunosuppressant market: Drug overview
TABLE 7 Oral drugs market: Drug overview
TABLE 8 Injectable market: Drug overview
TABLE 9 Intravenous market: Drug overview
TABLE 10 North America multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 11 U.S. multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 12 Canada multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 13 Europe multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 14 UK multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 15 Germany multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 16 Asia Pacific multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 17 China Multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 18 India Multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 19 Latin America multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 20 Brazil multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 21 MEA multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 22 South Africa multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 23 MEA multiple sclerosis therapeutics market, by drug class, 2012 - 2024 (USD Million)
TABLE 24 MEA multiple sclerosis therapeutics market, by treatment, 2012 - 2024 (USD Million)

List of Figures

FIG. 1 Multiple Sclerosis Therapeutics: Market Segmentation
FIG. 2 Global Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 3 Multiple sclerosis therapeutics Market Dynamics
FIG. 4 Key Opportunities Prioritized
FIG. 5 Multiple sclerosis therapeutics market - Porter’s analysis
FIG. 6 Multiple sclerosis therapeutics market - PESTEL analysis
FIG. 7 Multiple sclerosis therapeutics Market Share By Drug Class, 2015 & 2024
FIG. 8 Global immunomodulators market, 2012 - 2024 (USD Million)
FIG. 9 Global Immunosuppressant market, 2012 - 2024 (USD Million)
FIG. 10 Multiple sclerosis therapeutics Market Share By Drug Class, 2015 & 2024
FIG. 11 Global oral market, 2012 - 2024 (USD Million)
FIG. 12 Global Injectable market, 2012 - 2024 (USD Million)
FIG. 13 Global Intravenous market, 2012 - 2024 (USD Million)
FIG. 14 Multiple sclerosis therapeutics Market Share by Region, 2015 & 2024
FIG. 15 North America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 16 U.S. Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 17 Canada multiple sclerosis therapeutics market, 2012 - 2024 (USD Million)
FIG. 18 Europe Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 19 UK Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 20 Germany Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 21 Asia Pacific Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 22 China Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 23 India Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 24 Latin America Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 25 Brazil Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 26 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 27 South Africa Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)
FIG. 28 MEA Multiple sclerosis therapeutics Market, 2012 - 2024 (USD Million)